Jones Trading Reiterates Buy Rating on Enliven Therapeutics
Jones Trading maintains its Buy rating on Enliven Therapeutics, setting a $70 price target, a 37.93% upside from the current price.
Key Points
- Jones Trading reiterated its Buy rating on Enliven Therapeutics (NasdaqGS:ELVN) with a $70 price target on June 29, 2026.
- Jones Trading's $70 price target implies 37.93% upside from Enliven Therapeutics, Inc.'s ($ELVN) current $50.75 share price.
- Shares of Enliven Therapeutics traded near $50.08 on Monday, with a market cap of approximately $3.58 billion.
- Peers like Polar Capital increased their stake by 44.2%, while insiders such as Helen Louise Collins made notable trades.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jones Trading reiterated its Buy rating on Enliven Therapeutics, Inc. (NasdaqGS:ELVN) on June 29, 2026, maintaining a price target of $70. This update comes as the stock traded near $50.08 on Monday.
Jones Trading vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Enliven Therapeutics
Polar Capital Holdings PLC increased its stake in Enliven Therapeutics by 1,552,253 shares, ending with 5,065,933 shares valued at about $198.6 million, marking a 44.2% increase. BlackRock, Inc. also added 71,381 shares to its holdings, bringing its total to 3,684,707 shares worth roughly $144.4 million, a 2.0% increase. In contrast, Commodore Capital LP reduced its position by 1,417,809 shares, leaving it with 3,275,000 shares valued at $128.4 million, a 30.2% decrease. FMR LLC trimmed its holdings by 278,389 shares, resulting in 6,829,246 shares valued at about $267.7 million, a 3.9% decrease.
Enliven Therapeutics, Inc. Stock Down 12.3%
Shares of Enliven Therapeutics traded near $50.08 on Monday. The company has a market cap of around $3.58 billion, with a forward P/E ratio of -20.6, indicating it currently isn't profitable. Its beta is 0.396, suggesting lower volatility compared to the market. The stock's 52-week range is between $14.79 and $50.56, with a 50-day moving average of $42.11 and a 200-day moving average of $28.94. Enliven Therapeutics has a strong liquidity position, with a current ratio of 40.32 and a quick ratio of 39.38, and a low debt-to-equity ratio of 0.067.
$ELVN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Enliven Therapeutics, Inc.
Recent insider activity at Enliven Therapeutics includes OrbiMed Advisors LLC selling 860,123 shares on June 22, 2026. On June 17, 2026, CFO Benjamin Hohl sold 6,018 shares at an average price of $43.80 under a planned sale and also bought 6,018 shares at $2.48. Chief Medical Officer Helen Louise Collins sold 5,000 shares at an average price of $43.80 under a planned sale and also purchased 5,000 shares at $2.48.
Analysts Set New Price Targets
On June 29, 2026, Jones Trading reiterated its Buy rating on Enliven Therapeutics with a $70 price target. Earlier in June, Stifel initiated coverage with a Buy rating and a $60 target. Mizuho maintained its Buy rating with a $62 target on June 2, 2026. The overall analyst consensus is a Buy, with an average target price of $60.11 based on nine analyst opinions.
About Enliven Therapeutics
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boulder, Colorado. It focuses on developing small molecule inhibitors for cancer treatment. The company is working on ELVN-001, a kinase inhibitor for chronic myeloid leukemia, and ELVN-002, an inhibitor targeting HER2 mutant tumors in non-small cell lung cancer. Founded in 2019, it is led by CEO Samuel S. Kintz and employs 61 people.
Bottom Line
Enliven Therapeutics is drawing attention with its innovative cancer treatments and recent analyst support. While Jones Trading's reiterated Buy rating reflects confidence, investors should remember that these ratings are backward-looking and may not reflect current market conditions.
Get Enliven Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ELVN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.